Our Private Equity Group is considered the go-to practice for complex, bespoke and firm-defining transactions. With clients ranging from the world’s leading institutional asset managers to prominent middle-market private equity and growth equity firms, we offer comprehensive advice to general partners, limited partners, co-investors and other equity stakeholders, as well as portfolio companies, lenders and financial sponsor groups. The depth and continuity of our relationships across the industry gives us a nuanced understanding of each client’s objectives and allows us to provide seamless, efficient counsel across the investment lifecycle.
PCI Pharma To Acquire LSNE
- Client News
- October 12, 2021
Paul, Weiss is advising PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global integrated solutions provider and portfolio company of Kohlberg & Company, LLC, in its acquisition of Lyophilization Services of New England, Inc. (LSNE) from global private equity firm Permira. LSNE is a New Hampshire-based premier contract development and manufacturing organization (CDMO).
The transaction will expand PCI’s breadth of services as a global CDMO, building on PCI’s expertise in biologics packaging and specialty manufacturing. It will add five FDA-approved facilities in the U.S. and Europe, with a sixth expecting approval over the coming months, and three additional facilities under development, to PCI’s global 30-site network. Financial terms of the deal were not disclosed.
The Paul, Weiss team includes, among others, corporate partners Angelo Bonvino and Thomas de la Bastide and counsel Julie Martinelli and Suhan Shim; tax partner Lindsay Parks; intellectual property partner Charles Googe; litigation partner Aidan Synnott and counsel Peter Jaffe and Steven Herzog; real estate partner Peter Fisch; executive compensation counsel Meghan Fox and Reuven Falik; international trade counsel Richard Elliott; and antitrust counsel Marta Kelly.